These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 730410)
1. The pharmaceutical industry: a further study in corporate power. McCraine N; Murray MJ Int J Health Serv; 1978; 8(4):573-88. PubMed ID: 730410 [TBL] [Abstract][Full Text] [Related]
2. The pharmaceutical industry--prices and progress. Scherer FM N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432 [No Abstract] [Full Text] [Related]
3. Post-patent barriers to entry in the pharmaceutical industry. Scherer FM J Health Econ; 1985 Mar; 4(1):83-7. PubMed ID: 10271148 [No Abstract] [Full Text] [Related]
4. Pharmaceutical research: cost savings through innovation. Cohen KR; Levy RA AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463 [No Abstract] [Full Text] [Related]
5. The pharmaceutical industry: a study in corporate power. Murray MJ Int J Health Serv; 1974; 4(4):625-40. PubMed ID: 4463170 [No Abstract] [Full Text] [Related]
6. Drug firms' woes may slow profit growth. Dine DD Mod Healthc; 1989 Feb; 19(7):52. PubMed ID: 10291927 [No Abstract] [Full Text] [Related]
7. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures. Grabowski H Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474 [TBL] [Abstract][Full Text] [Related]
8. [Current challenges for the pharmaceutical research industry]. Chalchat B Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118 [TBL] [Abstract][Full Text] [Related]
9. Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry. McRae JJ; Tapon F J Health Econ; 1985 Mar; 4(1):43-61. PubMed ID: 10271145 [TBL] [Abstract][Full Text] [Related]
10. Precipitating factors for pharmaceutical firms. McCarthy R State Health Care Am; 1997; ():39-43. PubMed ID: 10168083 [No Abstract] [Full Text] [Related]
11. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses. Tang WL Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553 [TBL] [Abstract][Full Text] [Related]
13. Government initiatives in the development of a pharmaceutical industry in Australia. Hirst CA Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):57-61. PubMed ID: 1623637 [TBL] [Abstract][Full Text] [Related]
14. [The drug industry. A leading economic activity. 1. The companies The medication market]. Veylon R Nouv Presse Med; 1976 Jan; 5(2):97-101. PubMed ID: 1264652 [No Abstract] [Full Text] [Related]
15. The economics of priority review vouchers. Dimitri N Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445 [TBL] [Abstract][Full Text] [Related]
16. Patent indicators: a window to pharmaceutical market success. Guo Y; Hu Y; Zheng M; Wang Y Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022 [TBL] [Abstract][Full Text] [Related]
17. Biotechnology in pharmaceuticals: the Japanese challenge. Dibner MD Science; 1985 Sep; 229(4719):1230-5. PubMed ID: 3898361 [TBL] [Abstract][Full Text] [Related]
18. The extraterritoriality of US patents on the pharmaceutical industry. Park H Pharm Pat Anal; 2014 Sep; 3(5):491-8. PubMed ID: 25374318 [TBL] [Abstract][Full Text] [Related]
19. Eli Lilly enters venture capital arena. Fletcher L Nat Biotechnol; 2001 Nov; 19(11):997-8. PubMed ID: 11689830 [No Abstract] [Full Text] [Related]
20. Trendspotting: betting strong but playing safe. Anderegg MH; Thayer JM; Williams KM Nat Biotechnol; 2006 Jul; 24(7):741-3. PubMed ID: 16924774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]